logo-loader
RNS
viewDiurnal

Diurnal Group PLC - Change of Adviser

RNS Number : 2704O
Diurnal Group PLC
29 May 2020
 

29 May 2020

 

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Change of Adviser

 

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the appointment of Panmure Gordon (UK) Limited ("Panmure Gordon") as sole corporate broker with immediate effect. Panmure Gordon will continue to act as the Company's nominated adviser.

 

 

 

For further information, please visit www.diurnal.co.uk or contact:



Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer


Richard Bungay, Chief Financial Officer




Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

+44 (0)20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl


Corporate Broking: James Stearns




FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway


Victoria Foster Mitchell


 

 

Notes to Editors

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia and adrenal insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
APPFLFLEEAITFII

Quick facts: Diurnal

Price: 47.6

Market: AIM
Market Cap: £57.35 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE